Research analysts and the incentives behind a rating

Chapter 4 placed research in a disclosure-and-conduct regime rather than a suitability one. This chapter is what that regime actually requires, and why those particular requirements.

What counts as research

"Research services" under the regulations is broad, covering the preparation or publication of a research report, issuing research analysis, making a buy/sell/hold recommendation, giving a price target or stop loss target, offering an opinion concerning a public offer, recommending a model portfolio, and providing trading calls.

A "research report" means a written or electronic communication including research analysis, a research recommendation or an opinion concerning securities, addressed "to the clients or other persons or group of persons or general public" — and expressly applies "whether or not any such person has the job title of 'research analyst'".

That last clause is the one people miss. The obligations attach to the activity, not to the business card. Running a channel that issues price targets makes you a research analyst in substance, and the registration requirement follows.

Why sell-side research skews positive

This is a structural story, and it is worth getting right because the rules are designed against it.

Access. An analyst needs management to take their calls, attend their conferences, answer questions. A sell rating can end that access, and an analyst without access produces worse research — so the punishment for a negative view falls on their ability to do the job.

The employer's other business. If the firm also wants to underwrite the company's next issue or handle its treasury, a sell rating on that company is commercially expensive to the firm, whatever the analyst intended.

Asymmetric consequences. A buy rating that fails looks like bad luck, because most things go up sometimes. A sell rating that fails is conspicuous, and the company will complain. The reputational cost is not symmetric around being wrong.

Nobody has to be dishonest for any of this to operate. Each pressure acts on which companies get covered, how hard the analyst pushes, and how a marginal judgement resolves. That is why the Indian rules do not ask for impartiality — they restrict behaviour that can be observed.

The trading restrictions

Regulation 16 is the sharpest part of the regime.

Personal trading is supervised. Trading by individuals employed as research analysts must be "monitored, recorded and wherever necessary, shall be subject to a formal approval process."

The window around publication. Analysts and their associates "shall not deal or trade in securities that the research analyst recommends or follows within thirty days before and five days after the publication of a research report."

Thirty days before is the part worth understanding. Five days after stops you selling into the demand your own report creates. Thirty days before stops you accumulating a position in order to publish. The longer leg addresses the harder abuse, which is the one the public cannot see.

No trading against your own view. An analyst "shall not deal or trade directly or indirectly in securities that he reviews in a manner contrary to his given recommendation." Publishing a buy while selling is prohibited outright.

No pre-IPO stock in your own sector. An analyst must not "purchase or receive securities of the issuer before the issuer's initial public offering, if the issuer is principally engaged in the same types of business as companies that the research analyst follows or recommends."

For firms, segregation buys relief. Those restrictions apply to a research entity "unless it has segregated its research activities from all other activities and maintained an arms-length relationship between such activities" — the same trade as chapter 5's regulation 15(3), extended to research.

The narrow exceptions prove the rule. Trading may be permitted despite the window in the case of "significant news or event" concerning the company, or an "unanticipated significant change in the personal financial circumstances" of the analyst — but only with prior written approval under approved internal policies. The exception is for genuine emergencies and is documented, which is what stops it swallowing the rule.

The compensation rule

Regulation 17 attacks the second explanation above directly.

A research entity "shall not pay any bonus, salary or other form of compensation to any individual employed as research analyst that is determined or based on any specific merchant banking or investment banking or brokerage services transaction."

And the compensation of analysts must be reviewed, documented and approved annually by the board or a committee "which does not consist of representation from its merchant banking or investment banking or brokerage services divisions."

Both halves are needed. The first severs the link between a deal and an analyst's pay. The second stops the people who want the deal from being the people who set the analyst's pay — because an incentive routed through a performance review is just as effective as one routed through a bonus formula.

Disclosure, as the backstop

Where the conflict cannot be removed, it must be stated. Research analysts must disclose material information about themselves including business activity and disciplinary history, whether they or their associates received any compensation from the subject company in the past twelve months, and whether the subject company is or was a client during the twelve months preceding distribution of the report, along with the types of services provided. Distributing someone else's research requires disclosing that third party's material conflicts or pointing to where they are disclosed.

In a public appearance — television, a video, a public talk — the person must disclose their name, registration status and details of their financial interest in the subject company. There is also a restriction on public appearances concerning an issuer within twenty-five days of an offering.

So when a guest on a business channel states their registration and holdings, that is not a formality. It is regulation 4's and chapter 3's weakest remedy doing the only job left after the structural ones have done theirs.

Working the problem

Three structural explanations for the preponderance of buy ratings, and what Indian law does about each.

1. Access to management. Negative coverage costs the analyst the raw material of their work. Not addressed, and not addressable. No regulation can compel a company to return an analyst's calls. This is the residual conflict in the system, and it is why a sell rating from a well-regarded analyst carries more information than a buy rating: it was expensive to publish.

2. The employer's investment banking and brokerage relationships. Directly addressed, and this is the strongest part of the regime — regulation 17 forbids pay based on a specific banking or brokerage transaction and keeps those divisions off the committee setting analyst pay, while regulation 16(5) requires segregation and arm's length where a firm does both. Backed by disclosure of compensation received from, and client relationships with, the subject company.

3. Asymmetric reputational cost of being wrong. Not addressed. It is a feature of how audiences react, not conduct that can be prohibited.

And a fourth, which the rules treat most severely: the analyst or firm holding the stock they are recommending. Addressed hardest — the thirty-day and five-day window, the ban on trading contrary to your own recommendation, the pre-IPO prohibition, and monitored personal trading. The pattern is instructive: where the conflict can be removed by restricting an observable act, it is; where it lives in relationships and incentives, the law reaches for disclosure; and where it lives in human reaction, it is left alone.

The point

Sell-side research tilts positive for reasons that need no dishonesty: analysts depend on management access, their employers want the company's banking business, and being wrong on a sell is more conspicuous than being wrong on a buy. SEBI responds not by requiring impartiality but by restricting observable acts — no trading in a covered stock for thirty days before and five days after publication, no trading against your own recommendation, no pre-IPO stock in your own sector, and no pay tied to a specific banking or brokerage deal, with those divisions excluded from the committee that sets analyst pay. What remains, chiefly the dependence on access, is left to disclosure, which is why a sell rating carries more information than a buy.